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Abstract
Gestational diabetes mellitus (GDM) is one of the most common metabolic complications of pregnancy. Ever since
the first systematic evaluation of the oral glucose tolerance test by O’Sullivan and colleagues was carried out in
1964, there has been controversy with respect to the optimal screening and diagnostic criteria to detect GDM.
The recently proposed International Association of Diabetes and Pregnancy Study Groups (IADPSG) criteria for
GDM has found fairly widespread acceptance, but it is still debated by several societies. This review intends to
provide an overview of the evolution of the screening and diagnostic criteria for GDM. Debatable issues
regarding optimal screening strategies, especially in the low resource settings of low and middle income
countries are highlighted. The recent Women in India with GDM Strategy (WINGS) project carried out in Chennai,
India tried to develop a Model of Care for GDM suitable for resource constrained settings. The findings related to
screening and diagnosis of GDM based on WINGS are also highlighted in this review. Based on the WINGS
experience we believe that despite the constraints in low and middle income countries at the present time, the
IADPSG criteria appears to be the best. This will also help to bring out a uniform criteria for screening and
diagnosis of GDM worldwide.
Keywords: Screening, IADPSG, Gestational diabetes mellitus, Low middle income countries, WINGS, India, Asian
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Background
The criteria for diagnosing diabetes outside of pregnancy,
has evolved over time and have been largely accepted by
major diabetes organizations worldwide. However, the
screening and diagnosis of gestational diabetes mellitus
(GDM) continues to be a contentious issue. Notwithstand-
ing decades of research and several international work-
shops devoted to GDM, there is still no consensus among
international bodies on a uniform global approach to
screening and diagnosis of GDM [1]. Indeed, guidelines for
GDM screening and diagnosis vary among countries and
between major societies worldwide. Often, even within a
country, there is lack of consensus between the diabetes
and obstetric societies, with each of them recommending a
different approach [2].
The lack of consensus regarding the screening and
diagnostic criteria for GDM means that different sets of
women would be identified as having GDM by the dif-
ferent criteria. The guidelines used depend on several
factors like the availability of infrastructure, cost consid-
erations and patient convenience. Poor dissemination of
information and availability of resources could be some
of the reasons for these conflicting guidelines used in
different settings.
Controversies in screening and diagnosis of GDM
The terms “screening” and “diagnosis” are often used
interchangeably. A screening test for GDM identifies
women at greater or lower risk of GDM depending on a
particular glucose threshold. Those exceeding the
threshold in the screening test should then proceed to a
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definitive diagnostic test, which provides a definitive an-
swer to the presence or absence of GDM.
There has been a lot of controversy in literature with
respect to almost all aspects of screening for GDM.
These include many fundamental questions such as why
and how to screen for GDM, universal screening or
selective screening, one step procedure or two step
procedure, early (first trimester) screening or second
trimester screening etc. A detailed discussion on each
of these points would be beyond the scope of this
article. Hence we will restrict ourselves, in the first
part of this review to the historic evolution of the
various diagnostic criteria over time. The second part
of the article will focus on the challenges in screening and
diagnosis of GDM in low resource settings, specifically
drawing experience from the Women in India with GDM
Strategy (WINGS) [3, 4] project which was recently
completed in southern India.
Historical evolution of diagnostic criteria for GDM
The O’Sullivan and Mahan criteria
First proposed in 1964, the O’Sullivan and Mahan [5] cri-
teria formed the basis for the majority of criteria that sub-
sequently evolved. O’Sullivan and Mahan suggested the
use of a 50 g 1 h glucose challenge test (GCT) to screen
for GDM followed by a diagnostic (confirmatory) test in
those who were GCT positive (i.e., 1 h post glucose load
exceeds 140 mg/dl) using 100 g 3-h oral glucose tolerance
test (OGTT). These criteria were based on a series of 752
women who underwent OGTT during pregnancy. These
thresholds (Table 1) were based on venous whole blood
samples analysed by the Somogyi-Nelson method and
were based on their ability to predict maternal diabetes
subsequent to pregnancy. They came into widespread use
in the late 1970s.
The National Diabetes Data Group and the Carpenter &
Coustan criteria
Over the years, there was a universal change in laboratory
techniques in glucose assay methods. The less specific
Somogyi-Nelson method was replaced by enzyme based
assays which were now performed on plasma, rather than
whole blood. Thus the National Diabetes Data Group
(NDDG) [6] in 1979 proposed thresholds that were ap-
proximately 15 % higher than the original O’Sullivan and
Mahan cut points.
Subsequently in 1982, Carpenter and Coustan intro-
duced a correction factor and modified the O’Sullivan and
Mahan criteria empirically by adjusting for the differences
in assay methods. This was later validated by Sacks et al.
[7] and thus the famous Carpenter and Coustan criteria
for GDM came into existence and soon became widely
accepted [8].
American Diabetes Association (ADA) criteria for GDM
The ADA endorses the Carpenter and Coustan criteria
and recommends that women with high risk of GDM
(Table 2) undergo glucose testing as early as possible
during pregnancy [9]. A fasting plasma glucose (FPG)
≥126 mg/dl (7.0 mmol/l) or a random blood glucose
≥200 mg/dl (11.1 mmol/l) is diagnostic of pregestational
diabetes and has to be confirmed early in pregnancy.
The ADA recommends that the testing for GDM at 24–
28 weeks be done either by one step approach using a
100 g OGTT or by two step process, with an initial test
using 50 g GCT followed by the diagnostic OGTT using
100 g glucose load [9].
The World Health Organization (WHO) 1999 criteria for GDM
In 1999, a WHO Expert Group recommended that preg-
nant women who met the WHO criteria for impaired





Glucose threshold mg/dl (mmol/l)
Fasting 1 h 2 h 3 h
O’Sullivan & Mahan 1964 2 step 100 90 (5.0) 165 (9.2) 145 (8.1) 125 (6.9)
National Diabetes Data Group (NDDG) 1979 2 step 100 105 (5.8) 190 (10.6) 165 (9.2) 145 (8.1)
Carpenter & Coustan 1982 2 step 100 95 (5.3) 180 (10.0) 155 (8.6) 140 (7.8)
World Health Organization (WHO) 1999 1 step 75 126a (7.0) – 140 (7.8) –
American Diabetes Association (ADA) 2004 2 step 100 95 (5.3) 180 (10.0) 155 (8.6) 140 (7.8)
Latin American Diabetes Association (ALAD)b 2008 2 step 75 100 (5.5) – 140 (7.8) –
International Association of Diabetes and Pregnancy Study Groups (IADPSG) 2010 1 step 75 92 (5.1) 180 (10.0) 153 (8.5) –
World Health Organization 2013 criteria (revised, same as IADPSG) 2013 1 step 75 92 (5.1) 180 (10.0) 153 (8.5) –
National Institute for Health and Care Excellence (NICE) 2015 1 step 75 101 (5.6) – 140 (7.8) –
Adopted from (Vandorsten et al., 2011) [15]
Values in parenthesis are in mmol/l
aLater this fasting value was dropped
bCriteria for the diagnosis of gestational diabetes in selected countries of the Americas. Final report of the Pan American Conference on Diabetes and Pregnancy [32]
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glucose tolerance (IGT) in the non-pregnant state, i.e.,
140 mg/dl (7.8 mmol/l) be classified as GDM. However,
they had also included a FPG ≥126 mg/dl (7.0 mmol/l)
[10]. Soon it was realized that the fasting ≥126 mg/dl
(7.0 mmol/l) level was inappropriate as it is diagnostic of
diabetes in the non-pregnant state. Hence it was later
dropped and subsequent studies used only the 2 h post
glucose cut point of 140 mg/dl (7.8 mmol/l) for diagno-
sis [11, 12]. In 2013, the WHO essentially dropped its
1999 criteria and endorsed the International Association
of Diabetes and Pregnancy Study Groups (IADPSG) cri-
teria that are discussed below.
Drawbacks of the earlier criteria
Each of the above criteria had some drawback or the
other. The O’Sullivan and Mahan criteria were derived
mathematically and were validated for future diabetes in
the mother rather than the outcomes of pregnancy. The
WHO 1999 criteria, also predicted future development
of type 2 diabetes in mothers and were simply based on
criteria for IGT used in non-pregnant adults without
taking into account the changes in carbohydrate metab-
olism brought about by pregnancy. The ADA criteria
was based on older data. Thus it was clear that newer,
evidence based, criteria validated by their ability to pre-
dict adverse pregnancy outcomes in both mother and
the baby, were urgently needed.
The Hyperglycemia and Adverse Pregnancy Outcomes
(HAPO) study
To deal with the wide disparity in diagnostic testing and
to clarify the unanswered questions regarding the associ-
ation of glucose with risks of adverse pregnancy outcomes,
the Hyperglycemia and Adverse Pregnancy Outcomes
(HAPO) study was planned. HAPO was a large multi na-
tional and multi center study, which included over 23,000
pregnant women [13]. OGTTs were administered between
24–32 weeks gestation in a heterogenous and an ethnic-
ally diverse group of pregnant women. Results of the
HAPO study showed a linear relationship between glucose
values and several primary (umbilical cord-blood C-
peptide level, birth weight, neonatal hypoglycemia, and
rate of cesarean delivery) and secondary outcomes (fetal
adiposity, preeclampsia, birth trauma, admission to NICU,
shoulder dystocia). These were directly related to the
levels of fasting as well as independently, to the 1 h, and
2 h post-challenge glucose values. The major conclusion
of the study was that the risk of adverse pregnancy out-
comes continuously increased as a result of elevated ma-
ternal fasting or post load glycemia measured at 24–28
weeks gestation.
International Association of Diabetes and Pregnancy
Study Groups (IADPSG) criteria
On the basis of the HAPO data, the International Asso-
ciation of Diabetes and Pregnancy Study Groups
(IADPSG) panel suggested a single step 75 g OGTT to
be done in all pregnant women at 24–28 weeks of gesta-
tion [14]. Glucose values which yielded an odds ratio
(OR) of 1.75, i.e., which had a 75 % increase in risk of
developing 3 combined primary outcomes (more than
90th centile of birth weight, total body adiposity based
on skin folds and cord blood C-peptide levels). The diag-
nosis was to be made if any one of the values for fasting
plasma glucose, 1-h glucose, or 2-h glucose equaled or
exceeded the diagnostic threshold as shown in Table 3.
IADPSG criteria also recommended the threshold for
the diagnosis of GDM as well as overt diabetes at first
trimester. Following the IADPSG recommendations, sev-
eral other guidelines now recommend screening in early
trimester to detect overt diabetes especially in high-risk
groups [9, 15–17].
Controversy surrounding GDM diagnosis in early
pregnancy
The IADPSG recommends a threshold of ≥ 92 mg/dl
(5.1 mmol/l) [14] to diagnose GDM in early pregnancy.
This was not based on any data, but on a consensus to
use the same FPG cut off of 92 mg/dl which is used at
24–28 weeks to be used at any point of time during
Table 2 Risk factors to screen for GDM [Recommended by the
American Diabetes Association (ADA) [9]]
• Age ≥25 years
• BMI ≥25 kg/m 2 in Americans and BMI ≥23 kg/m 2 in Asian Americans
• High risk ethnic groups – South Asian, Aboriginal, Hispanic
• Previous history of GDM
• Family history of type 2 diabetes
• History of poor obstetric outcomes – congenital malformations, still
birth etc.
Table 3 IADPSG criteria for diagnosis of GDM and overt





Overt diabetes if, FPG≥ 126 mg/dl
(7.0 mmol/l)
Or random plasma glucose≥
200 mg/dl (11.1 mmol/l)
Or HbA1c≥ 6.5 %
GDM if,
FPG≥ 92 mg/dl (5.1 mmol/l) but
<126 mg/dl (7.0 mmol/l)




75 g OGTT Pre existing diabetes if
FPG≥ 126 mg/dl (7.0 mmol/l)
GDM if,
FPG≥ 92 mg/dl (5.1 mmol/l)
1 h ≥ 180 mg/dl (10.0 mmol/l)
2 h ≥ 153 mg/dl (8.5 mmol/l)
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pregnancy to diagnose GDM. It has therefore been a
subject of intense debate. However in support of this, a
recent study from Australia has shown that high risk
women, diagnosed with GDM at less than 12 weeks of
gestation had adverse pregnancy outcomes similar to
that seen in women with pre existing diabetes [18]. This
justifies the diagnosis of GDM early in pregnancy.
In contrast, studies from Italy and China have shown
that using such low FPG cut offs is inappropriate to
diagnose GDM in early pregnancy [19, 20]. Corrado et
al. [19] showed no correlation between OGTT at 24–28
weeks and the FPG in early pregnancy. Zhu et al. [20]
showed that not all women with FPG ≥92 mg/dl
(5.1 mmol/l) in the first trimester developed GDM during
24–28 weeks. These authors have shown that FPG at first
trimester was not consistent with FPG at 24–28 weeks
since less than one third of women maintained ≥92 mg/dl
(5.1 mmol/l) between first trimester and 24–28 weeks.
However, they do accept that doing an FPG at first visit
could be useful in diagnosing undiagnosed overt diabetes.
Because of the low fasting cut point, the IADPSG cri-
teria has been reported to result in increased prevalence
rates of GDM and this increases the burden on the
health care system in many countries [21–23]. Very few
studies have addressed the cost effectiveness of this cri-
teria. Uncertainties about relevance of treating milder
GDM cases and lack of clinical trials addressing these is-
sues are other criticisms of the IADPSG criteria [24].
In response to these objections, the members of the
IADPSG council in a recent publication, suggested
that the identification of GDM in early pregnancy
using FPG ≥92 mg/dl (5.1 mmol/l) was not justified
due to insufficient evidence. They recommend identi-
fying only women with HbA1c of ≥5.9 % in early
pregnancy, who were at risk of developing adverse
pregnancy outcomes [25].
Adoption of IADPSG criteria by various scientific bodies
Though the IADPSG recommendations for first trimes-
ter diagnosis of GDM have been questioned, their rec-
ommendations for diagnosing GDM at 24–28 weeks are
based on evidence that correlate maternal glucose con-
centrations to fetal outcomes. These recommendations
also reflect a consensus view and have been accepted by
a large number of scientific bodies. In 2011, the ADA
endorsed the IADPSG criteria [26]. ADA recommended
that all pregnant women not known to have prior dia-
betes undergo a 75 g OGTT at 24–28 weeks. Although
the thresholds recommended by IADPSG are only min-
imally different from the ADA criteria, the prevalence of
GDM would still be higher, if IADPSG criteria were
used. This is because while the ADA uses 100 g OGTT,
requires 2 elevated readings, the IADPSG uses the 75 g
load and requires only one abnormal value.
Duran et al. [27], prospectively studied two groups of
women: – one group identified as GDM by the Carpen-
ter and Coustan criteria and the other by the IADPSG
criteria. Both groups after receiving the same treatment
and follow up, were evaluated for health outcomes. This
study, one of the first to address the economic benefits
of the one step IADSPG criteria, had 4 major conclu-
sions: One, applying IADPSG criteria was associated
with decrease in adverse pregnancy outcomes like pre-
eclampsia, cesarean deliveries, macrosomia and LBW,
neonatal intensive care unit admission, compared to the
Carpenter and Coustan criteria. Second, IADPSG criteria
identifies women who had milder GDM, who were con-
sidered to be normal by Carpenter and Coustan criteria,
thereby increasing the prevalence rates. Third, IADPSG
criteria did not lead to overtreatment of GDM as pa-
tients needing insulin therapy were not different from
the other group of GDM identified by Carpenter and
Coustan criteria. Lastly, IADPSG criteria did not in-
crease the health care costs since with the improvement
in pregnancy outcomes, rate of cesarean deliveries and
number of NICU admissions were reduced. Results from
a study in China [28], comparing the IADPSG and the
Carpenter and Coustan criteria reported that IADPSG
criteria showed better pregnancy outcomes (lower pri-
mary cesarean section and lesser neonatal morbidity)
than the Carpenter & Coustan criteria, but at the ex-
pense of increased prevalence of GDM.
As already mentioned, in 2013, the WHO also ac-
cepted the IADPSG criteria [29]. Other organizations
like the Endocrine Society [17] and the Australian Dia-
betes in Pregnancy Society (ADIPS) [30] and recently
the International Federation of Gynecology and Obstet-
rics (FIGO) [31] have also accepted the IADPSG criteria.
In 2013, the National Institute of Health (NIH) con-
vened a consensus meeting on GDM to review the recom-
mendations by IADPSG criteria. The panel report stated
that there was insufficient evidence to support the single
step approach proposed by IADPSG and therefore recom-
mended that the 2 step approach of screening with 1 h
50 g GCT followed by 100 g GTT as a diagnostic test for
GDM, be continued [15]. The American College of Obste-
tricians and Gynecologists also support the 2 step ap-
proach in their guidelines released in 2013 [16].
Criteria for GDM diagnosis in South and Central America
and Europe – trending towards IADPSG criteria
While some Latin American countries have adopted the
IADSPG criteria, many have incorporated local modifi-
cations to the criteria due to practical difficulties in
implementing in low resource settings. A recent compil-
ation of information from the Pan American Conference
on Diabetes and Pregnancy Report 2015 [32] elucidated
much needed data on the different criteria followed in
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different South and Central American countries. The
Argentine Diabetes Society (SAD) based on a recent
multicentric study which compared the IADPSG cri-
teria and the Latin American Diabetes Association
(ALAD) criteria (Table 1) showed prevalence of GDM to
be 10.4 % by ALAD as against 26.7 % by IADPSG criteria,
and hence recommends following the ALAD criteria for
GDM diagnosis. Other countries like Guyana, Guatemala,
Nicaragua, Colombia and Peru have adopted the IADPSG
criteria. However, not all of them follow the IADPSG cri-
teria as a one step process as recommended, but as two
step process following an abnormal GCT.
Similar methods are followed in some parts of Europe,
where Germany for example follows a 75 g OGTT of
IADPSG criteria following a 50 g GCT [33]. It is to be
noted however that this method of GCT followed by
IADPSG criteria is currently not validated. Ireland,
France and some parts of Belgium have adopted the
IADPSG criteria [33], but only in high risk individuals.
With the aim of developing a consensus for GDM
screening and diagnosis across Europe, the European
Board and College of Obstetrics & Gynecology (EBCOG)
in association with the European Association for the
Study of Diabetes (EASD) have proposed screening for
overt diabetes at first antenatal visit using cut off for dia-
betes outside of pregnancy and to perform GDM screening
at 24–28 weeks with a 2 h 75 g OGTT as recommended
by the IADPSG. Due to lack of evidence on classifying
GDM using FPG ≥92 mg/dl (5.1 mmol/l) in first trimester
or first antenatal visit, the EBCOG states that no
clear recommendations can be made on diagnostic
criteria for GDM in early pregnancy [33].
National Institute for Health and Care Excellence (NICE)
2015 criteria
Initially the NICE guidelines had recommended the
same criteria for GDM diagnosis as the WHO 1999 cri-
teria. In 2015, NICE [34] modified the WHO 1999 cri-
teria and on the basis of health economic analysis,
revised their guidelines recommending a fasting cut
points of 101 mg/dl (5.6 mmol/l) in addition to the 2 h
post glucose value of 140 mg/dl (7.8 mmol/l). At the
first antenatal booking appointment, screening for GDM
is done through risk factor based assessment. Women
with any one of the risk factors are then advised to
undergo testing for GDM using the 2 h 75 g OGTT and
diagnosis is made as per the thresholds mentioned in
Table 2. In women with a previous history of GDM,
NICE 2015 recommends a 75 g 2 h OGTT immediately
after booking, whether in the first or second trimester
and a further 75 g 2 h OGTT at 24–28 weeks, if the test
was normal in the earlier visit.
The main difference between IADPSG criteria and
NICE 2015 guidelines is that while IADPSG criteria is
based on reducing risk of harm to both mother and
baby, the NICE 2015 is based on reducing the average
unit costs for selected adverse outcomes using health
economic modelling which compared the cost effective-
ness of NICE risk factor based screening with universal
screening. The analysis showed that the incremental cost
effectiveness ratios (ICER) in risk factor selected popula-
tion using NICE 2015 criteria was in the range of
£20,000 to £30,000 per quality adjusted life year (QALY),
as compared to an ICER of £47,000 in the subset without
risk factors. The model therefore did not support change
to universal testing as recommended by IADPSG [35].
However, while cost effectiveness is important, it is also
important to consider the burden of complications and its
effect on emotional and psychological wellbeing, which
cannot be measured in economic terms alone [36].
Challenges in screening and diagnosis of GDM in low
resource settings
Notwithstanding the scientific validity of any guideline,
there are constraints of applying these criteria in low
and middle-income countries (LMIC) where resources
are poor. In some remote rural areas, lack of access to a
standardized laboratory and resources for performing
the test are huge challenges that needs to be addressed.
Often, lack of trained phlebotomists to collect venous
blood samples, as required by most guidelines, pose a
serious challenge in ensuring universal screening. In
many rural locations, pregnant women have to travel
long distances to meet the doctor and women do not
routinely attend antenatal check up in fasting state un-
less and otherwise informed earlier. Hence bringing back
women to undergo the test in the fasting state could be
a challenge. Table 4 and 5 summarizes the health care
system barriers and the patient related barriers to
screening for GDM in low resource settings.
Diabetes in Pregnancy Study Group India (DIPSI) criteria
To address some of these barriers, the Diabetes in Preg-
nancy Study Group of India (DIPSI) introduced simplified
guidelines for screening and management of GDM in
India. DIPSI recommends that an OGTTcan be performed
using a 75 g glucose load, irrespective of whether the
woman is fasting or not, and a 2-h venous plasma glucose
(VPG) value of 140 mg/dl (7.8 mmol/l) be used as the
Table 4 Challenges in screening for GDM in low resource
settings – Health care system barriers
Health care system barriers
Lack of trained health care professionals
Lack of trained phlebotomists
Lack of diagnostic facilities and standardized laboratories
Storage and transport of blood samples
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single step definitive, screening and diagnostic test for
GDM. These guidelines were based on a single-centre
study [37] from southern India which reported a 100 %
sensitivity and 100 % specificity for this cut point com-
pared to the WHO 1999 criteria which also uses the same
cut point of 140 mg/dl [7.8 mmol/l] but with the OGTT
done in the fasting state.
In a resource limited setting like India, where nearly
70 % of the population lives in rural settings [38], DIPSI
felt that there was a need to develop a simple and eco-
nomical method of diagnosing GDM. The DIPSI criteria,
because of its sheer simplicity, has been widely accepted
and used in many parts of India and Sri Lanka [39] and
other South Asian countries. However, as shown below,
recent studies have not been able to reproduce the near
perfect sensitivity and specificity of the non fasting
DIPSI test compared to the fasting OGTT.
The WINGS project
Acknowledging the challenges for screening and manage-
ment of GDM in low resource settings, the International
Diabetes Federation (IDF) with an unrestricted support
from Abbott Fund, launched the Women in India with
GDM Strategy (WINGS) [3] project in collaboration with
the Madras Diabetes Research Foundation and the project
was carried out in Chennai in southern India. The aim of
the project was to improve the health outcomes of women
with GDM and their babies and to strengthen the capacity
of health facilities in low resource settings. The project
helped the development of a Model of Care for GDM,
which was then tested whether it was effective and feasible
for implementation in resource-constrained settings [4].
One of the aims of the WINGS project was to find a
cost effective screening strategy and the logical step was
to try to replicate the DIPSI results because if a non fast-
ing OGTT can be used it addresses several of the barriers
mentioned in Table 4 and 5.
Hence as one of the first objectives, the WINGS project
compared the non fasting OGTT with a standard fasting
OGTT for screening for GDM using both IADPSG and
the WHO 1999 criteria. The WINGS project showed that
the non-fasting OGTT had very low sensitivity (22.6 %)
compared to both the IADPSG criteria as well as the
WHO 1999 criteria (27.7 %) [40]. The specificity of the
DIPSI criteria was however found to be high - 97.8 and
97.7 % compared to the IADPSG and WHO 1999 criteria
respectively. Another study from Delhi, in north India also
confirmed the low sensitivity of the DIPSI criteria and
concluded that it would miss a substantial number of
GDM patients and these authors suggested that the
IADPSG criteria is most suitable for screening for GDM
in India [41]. A study from Sri Lanka, also confirmed that
the sensitivity of the DIPSI criteria was low (40.6 %) [42].
Indeed, the low sensitivity of the non-fasting OGTT was
shown several decades ago by Coustan et al. [43]. The
physiology of the non-fasting state, can explain the low
sensitivity of the non-fasting OGTT. After a woman con-
sumes a carbohydrate meal, blood glucose levels increase,
thereby stimulating insulin release. When a glucose load is
given at this point, blood glucose levels are blunted since
insulin levels are already elevated. The sensitivity of the
test therefore drops dramatically as shown in above men-
tioned studies. Hence the WINGS project supports all
international guidelines, which recommend that the diag-
nostic OGTT should be done after an overnight fast.
As pointed out earlier, in low resource settings, obtain-
ing venous plasma glucose samples is sometimes next to
impossible due to shortage of trained phlebotomists in
addition to limited access to standardized laboratories to
carry out venous glucose estimations. However, currently
almost all criteria for GDM require venous plasma sam-
ples for diagnosis of GDM. The question then arises,
what if it is impossible to obtain a venous blood sample?
In such situations, if screening for GDM is to be done at
all, the only alternative would be to use a hand held
blood glucose meter to perform capillary blood glucose
(CBG) testing. The advantage of using the CBG is that
even lay people can be trained to do the screening as it
serves as a portable, point of care device for screening.
Moreover, obtaining a finger prick sample is minimally
invasive when compared with venous blood draw and
hence more acceptable to the subjects [44]. Currently
however, the use of CBG for diagnosis of GDM is not
recommended by any association or guideline. The sec-
ond objective of the WINGS project was to compare
CBG estimations using hand held glucose meter and
venous plasma glucose (VPG) estimations. The results
showed that the CBG had a low sensitivity when com-
pared with VPG. Moreover, additional women, not identi-
fied by the IADPSG criteria to have GDM were picked up
by the CBG. In addition, the receiver operating character-
istic curve with different 2 h CBG cut points showed that
a 2 h CBG cut point of 126 mg/dl (7.0 mmol/l) had the
optimum sensitivity and specificity of 70.8 and 63 % com-
pared to the IADPSG criteria. If this cut point is lowered
to 120 mg/dl (6.6 mmol/l), the sensitivity improved to
78.3 %, and if lowered to 110 mg/dl (6.1 mmol/l), it im-
proved to 92.5 %. However, 50.1 and 68.9 % of women
Table 5 Challenges in screening for GDM in low resource
settings – Patient related barriers
Patient barriers
Coming for check up in the fasting state
Late contact with health care system
Lack of awareness about GDM and its complications
Distance to the primary health center/ higher centers
Undergoing the OGTT in the fasting state
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respectively, have to be referred for the definitive diagnos-
tic OGTT using VPG [45]. Hence the WINGS project
concluded that while the CBG cannot effectively replace
VPG for diagnosis of GDM it can perhaps be used as an
initial screening test (similar to the older GCT test) in
resource-constrained settings.
In summary, the WINGS project suggests that ideally,
and whenever feasible, a single step 75 g OGTT using
the IADPSG criteria should be done in the fasting state
and that VPG still remains the gold standard. However,
in resource limited settings, especially in the rural areas
of developing countries where getting all pregnant
women to come in a fasting state may be difficult, the
well validated two step procedure using the 50 g OGCT
in the non-fasting state as the screening test followed by
fasting OGTT for a definitive diagnosis can be contin-
ued. In situations where obtaining a venous sample is
impossible, the CBG could be used as an initial screen-
ing test by maximizing sensitivity by lowering the 2 h
cut points. Those who screen positive, could then be re-
ferred to higher centres for the definitive diagnostic
OGTT in the fasting state, using VPG.
Where does this leave the DIPSI criteria which is quite
widely used in India? As the specificity of DIPSI test is
good, women diagnosed by the DIPSI criteria most likely,
do have GDM. However, a substantial number of women
who have GDM are likely to be missed. Our suggestion
would be that in situations where all pregnant women
cannot be referred in the fasting state for a diagnostic
OGTT, the DIPSI non fasting test can be done as an initial
screening test but with a lower cut point to maximize the
sensitivity. Those who screen positive in this screening
test, can then be referred for a definitive OGTT done in
the fasting state. However, this needs to be tested for
validation as a two step technique by future studies.
Conclusions
The decision on the best strategy for screening and diag-
nosis should be made based on cost and availability of
the locally existing health facilities. Ultimately it is ideal
that all countries should use criteria that are internation-
ally accepted. All things considered, the IADPSG criteria
seems to be the most suitable at present for screening
and diagnosis of GDM. However there is a need for
studies on cost effectiveness of IADPSG criteria and its
applicability especially in resource constrained regions of
the world. Future research on GDM should be under-
taken with greater international collaboration, to address
the existing gaps in knowledge on this very important
public health problem.
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